Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Highlights| Protein Name | Adrenoceptor alpha 2C |
| Gene Name | ADRA2C |
| Uniprot | P18825 (Human); Q01337 (Mouse) |
| Synonym | ADRA2L2; ADRARL2; ADRA2RL2; ALPHA2CAR; adrenergic, alpha-2C-, receptor; alpha-2 adrenergic receptor subtype C4; alpha-2C adrenoceptor; alpha-2C adrenoreceptor; alpha-2CAR; alpha2-AR-C4 |
| Background | ADRA2C is one of the three defined subtypes of alpha-2-adrenergic receptors (alpha2A, alpha2B, and alpha2C), which are members of the G protein-coupled receptor family. These receptors regulate a wide range of physiological functions and are targets of clinically important antihypertensive and anesthetic agents. Moreover, they are found to play a critical role in regulating neurotransmitter release from sympathetic nerves and from adrenergic neurons in the central nervous system. Both mice and human have alpha2C expressed. Alpha2C receptors are present in the basal ganglia, olfactory tubercle, hippocampus, and cerebral cortex. However, alpha2C is the least characterized subtype of adrenergic receptors and still very little is known about the pathophysiological roles of this receptor. |
Creative Biolabs offers comprehensive range of membrane protein products empowers your unique research needs.
| CAT# | Product Name | Expression System | Protein Length | Solubilizing Agents |
| S01YF-1023-KX325 | NativeExtract™ Human ADRA2C Membrane Protein (Full length, Super Nanodisc) | HEK293 cell | Full length | Native Nanodisc |
| MPX3591K | MemDX™ Membrane Protein Human ADRA2C Expressed in vitro E.coli expression system, Full Length | E.coli cell-free | Full length | Detergent |
| Please for more products or customization | ||||
D***y: The recombinant expression system ensures proper folding, enabling robust ligand-binding assays and structural studies.
27/Jun/2023
R***n: Received a customized ADRA2C variant in 3 weeks with optimized solubility.
13/Mar/2024
ADRA2C Gene Therapy Development
We provide tailored solutions to meet your specific requirements. Please for more services.
Allelic Correction for ADRA2C Dysregulation
Creative Biolabs offers allelic correction services. Precision genome editing offers a transformative approach to address ADRA2C-linked pathologies. For instance, in vitro studies demonstrate that correction of nonsynonymous SNPs within the ADRA2C coding region restores receptor signaling dynamics in dysautonomia models. By deploying single-guide RNAs tailored to hypervariable promoter regions, researchers can achieve locus-specific repression or activation, enabling fine-tuned modulation of adrenergic signaling. Creative Biolabs' proprietary RNA design algorithms optimize specificity, minimizing off-target effects—a critical consideration for clinical translation.
AAV-Delivered shRNA for ADRA2C Silencing in Cardiovascular Disorders
Creative Biolabs offers AAV-delivered shRNA development services for ADRA2C silencing in cardiovascular disorders. Recombinant adeno-associated virus (AAV) vectors engineered with short hairpin RNA (shRNA) enable tissue-selective suppression of ADRA2C overexpression, a hallmark of refractory hypertension. Preclinical data reveal that intra-myocardial AAV9-shRNA administration in animal models reduces aberrant α2C-adrenoceptor density by 68%, attenuating pathological vasoconstriction. Creative Biolabs' optimized AAV serotype libraries, including cardiotropic variants, ensure efficient transduction with minimal immunogenicity.
Epigenetic Editing
Creative Biolabs offers epigenetic editing services. Catalytically inactive gene-editing tool fused with transcriptional repressors (e.g., KRAB) enables targeted epigenetic silencing of ADRA2C in sympathoexcitatory disorders. This approach circumvents permanent genomic alterations while achieving sustained downregulation. In a recent proof-of-concept study, KRAB delivery in stellate ganglia reduced ADRA2C mRNA levels by 82%, normalizing sympathetic tone in arrhythmia models. Creative Biolabs' epigenetic editing platforms integrate multiplexed guide RNA systems for simultaneous modulation of ADRA2C and comorbid targets, enhancing therapeutic synergies.
Creative Biolabs offers comprehensive and innovative services to drive the development of ADRA2C cell therapy. Please for more services.
Engineered T Cells with ADRA2C-Specific CARs
Creative Biolabs offers engineered T cells development services. CAR-T cells targeting ADRA2C-overexpressing neoplasms, such as neuroendocrine tumors, demonstrate potent cytotoxicity in co-culture assays. Second-generation CAR constructs incorporating 4-1BB costimulatory domains enhance persistence, with in vivo models showing complete tumor regression within 14 days. Creative Biolabs' lentiviral CAR delivery systems, validated for >95% transduction efficiency, are scalable under GMP-compliant protocols. Clients developing ADRA2C CAR-T therapies may benefit from our immunophenotyping panels to assess target engagement and cytokine release profiles.
ADRA2C+ Mesenchymal Stem Cells (MSCs) for Anti-Inflammatory Paracrine Signaling
Creative Biolabs offers ADRA2C+ mesenchymal MSCs development services. Genetic engineering of MSCs to overexpress ADRA2C augments their immunosuppressive capacity in autoimmune disorders. In murine colitis models, intravenously delivered ADRA2C+ MSCs secrete elevated TGF-β1 and IL-10, reducing colonic inflammation by 54% versus wild-type cells. Creative Biolabs' platforms enable stable ADRA2C upregulation without viral integration, ensuring regulatory compliance. Collaborative opportunities exist for clients pursuing IND-enabling studies, including biodistribution tracking via multimodal imaging.
Optogenetic Modulation of ADRA2C-Expressing Neural Circuits
Creative Biolabs offers optogenetic modulation of ADRA2C-expressing neural circuits services. Light-gated ion channels expressed in ADRA2C+ neurons permit spatiotemporal control of sympathetic outflow in hypertension. Fiber-optic implants in rodent models achieve real-time, reversible inhibition of ADRA2C signaling, lowering systolic blood pressure. Creative Biolabs' optogenetic toolkits, including cell-type-specific promoters and implantable devices, are customizable for preclinical testing.
Therapeutic innovation demands precision. Creative Biolabs' integrated platforms—spanning gene editing, viral vector engineering, and cell therapy development—are engineered to accelerate your ADRA2C program from concept to clinic. to schedule a confidential consultation. Let us tailor a roadmap that aligns with your therapeutic objectives, regulatory milestones, and commercialization goals. Your breakthrough starts here.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
